Objective:

To evaluate advancements in cancer screening technologies, focusing on liquid biopsy, multi-cancer early detection (MCED), and artificial intelligence (AI), while integrating technological and immunological perspectives more explicitly.

Approach:

Key Findings:

• Current organ-specific screening methods are limited by invasiveness, cost, and stage-dependent sensitivity.
• Liquid biopsy provides a minimally invasive alternative for molecular detection and longitudinal assessment.
• MCED tests aim to detect multiple cancer types through a single blood test, but their sensitivity varies by stage and tumor type.
• AI methods can enhance cancer screening but require external validation, integration into clinical workflows, and consideration of ethical implications.

Interpretation:

Technical detectability of biomarkers does not equate to clinical readiness, with many emerging technologies remaining investigational and requiring careful consideration of their clinical implications.

Limitations:

• Many biomarkers and AI models are still in the investigational phase.
• Clinical utility and regulatory oversight for new technologies are yet to be established, and equitable access must be considered.

Conclusion:

Future advancements will depend on standardized workflows, prospective validation, integration with existing screening systems, and addressing ethical considerations.

Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.